Comparative neurotoxicity of weekly non-break paditaxel infusions over 1 versus 3 h

Anti-Cancer Drugs

Volumn 14, Issue 10, 2003, Pages 785-792

  Mielke, Stephan ^a   Mross, Klaus ^b   Gerds, Thomas A ^b   Schmidt, Anja ^a   Wäsch, Ralph ^a   Berger, Dietmar P ^a   Lange, Winand ^c   Behringer, Dirk ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Johanniter Hospital Rheinhausen   (Germany)

Author keywords

Neurotoxicity; Paclitaxel; Phase III trial; Solid tumor; Weekly regimen

Indexed keywords

CREMOPHOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER RISK; CARDIOTOXICITY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG INFUSION; DYSPHAGIA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEARING DISORDER; HUMAN; INFECTION; KAPLAN MEIER METHOD; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEURALGIA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHARYNGITIS; PRIORITY JOURNAL; PROBABILITY; PRURITUS; RANDOMIZATION; SKIN DISEASE; STOMATITIS; TENDON REFLEX; THROMBOCYTOPENIA; VERTIGO; VOMITING;

EID: 1542510041     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200311000-00003     Document Type: Article

References (31)

1. Grem JL, Tutsch KD, Simon KJ, Albert DB, Willson JK, Tormey DC, et al. Phase I study of Taxol administered as a short intravenous infusion daily for 5 days. Cancer Treat Rep 1987; 71:1179-1181.
2. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as 24-h infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5:1232-1239.
3. Spriggs DR, Tondini C. Taxol administered as a 120 hour infusion. Invest New Drugs 1992; 10:275-278.
4. Hainsworth JD, Greco FA. Paclitaxel administered by 1-h infusion. Cancer 1994; 74:1377-1382.
5. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, et al. Phase II trial of paclitaxel by 3-h infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-2581.
6. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654-2666.
7. Klaassen U, Wilke H, Strumberg D, Eberhardt W, Korn M, Seeber S. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast or ovarian cancer. Eur J Cancer 1996; 32A: 547-549.
8. Greco FA, Hainsworth JD. Pacitaxel (1-h infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II study. Semin Oncol 1997; 24:12-17.
9. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1990; 8: 1263-1268.
10. Tsavaris NB, Kosmas C. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. Cancer Chemother Pharm 1998; 42:509-511.
11. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte stimulating factor: neuromuscular toxicity is dose limiting. J Clin Oncol 1993; 11:2010-2020.
12. Roytta M, Raine S. Taxol induced neuropathy: chronic effects of local injection. J Neurocytol 1986; 15:483-496.
13. Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39:368-373.
14. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from Taxol and cisplatin chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35:304-311.
15. van Gerven JM, Moll JW, van den Bent MJ, Bontenbal M, van der Burg ME, Verweij J, et al. Paclitaxel induces cumulative mild neurotoxicity. Eur J Cancer 1994; 30A:1074-1077.
16. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Pacitaxel induced neuropathy. Ann Oncol 1995; 6:489-497.
17. Berger T, Malayeri R, Doppelbauer A, Krajnik G, Huber H, Auff E, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997; 33:1393-1399.
18. Greco FA, Thomas M, Hainsworth JD. One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am 1999; 5:179-191.
19. Frasci G, Comella P, Parziale A, Casaretti R, Daponte A, Gravina A, et al. Cisplatin/paclitaxel weekly schedule in advanced solid tumors. Ann Oncol 1997; 8:291-293.
20. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19:4216-4223.
21. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937-940.
22. Mielke S, Mross K, Glocker FX, Unger C, Behringer D. Neurotoxicity of paclitaxel infused weekly over one versus three hours: preliminary results of a phase III trial. Proc Am Soc Clin Oncol 2001; 20:107a (abstr 425).
23. Gelderblom H, Mross K, Tije AJ, Behringer D, Mielke S, Zomeren DM, et al. Comparative pharmacokinetics of unbound paclitaxel during 1 and 3-hour infusions. J Clin Oncol 2001; 20:574-581.
24. Mross K, Häring B, Holländer N, Mielke S, Behringer D, Unger C. Comparison of the 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results of a randomized trial. Onkologie 2002; 25:503-508.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-481.
26. Cox DR. Regression models and life-tables (with discussion). J R Statist Soc B 1972; 34:187-220.
27. Briasoulis E, Karavasilis V, Tzamakou E, Haidou C, Piperidou C, Pavlidis N. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose escalation study. Anticancer Drugs 2002; 13:481-489.
28. Mross K, Hauns B, Haring B, Bauknecht T, Meerpohl HG, Unger C, et al. Clinical phase I study with one-hour paclitaxel infusion. Ann Oncol 1998; 9:569-572.
29. Durand JP, Goldwasser F. Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anticancer Drugs 2002; 13:777-780.
30. Peltier AC, Russell JW. Recent advances in drug induced neuropathies. Curr Opin Neurol 2002; 15:633-638.
31. Wang MS, Davis AA, Culver DG, Glass JD. WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol 2002; 52:442-447.